Veradermics, Incorporated stock analysis
Want to see MANE full AI Analyst Report?
Veradermics, Incorporated (MANE) Stock Price & Analysis
MANE Stock Chart & Stats
- Day’s Range
- $128.24 - $136.97
- 52-Week Range
- $32.00 - $156.63
- Previous Close
- $135.29
- Volume
- N/A
- Average Volume (3M)
- 832.34K
- Market Cap
- $5.47B
- Enterprise Value
- $4.32B
- Total Cash (Recent Filing)
- $798.35M
- Total Debt (Recent Filing)
- $668.00K
- Price to Earnings (P/E)
- ―
- Beta
- 0.19
- Next Earnings
- Apr 05, 2027 (Est.)
- EPS Estimate
- -0.61
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Late-stage Clinical Validation
Positive results across two registration-directed studies provide meaningful clinical validation for VDPHL01. Efficacy, patient-reported benefits, and favorable safety in more than 1,000 participants strengthen the program’s late-stage positioning and could support future regulatory and commercial progress.
Clinical Safety And Durability
Twelve-month data add evidence that treatment benefits can persist beyond the initial evaluation period, while the reported tolerability profile reduces a key development risk. This combination supports continued advancement of VDPHL01 and may improve its potential treatment value if approved.
Strong Reported Cash Position
A reported $798.4 million liquidity balance provides substantial resources for continued clinical development and preparations for a potential launch. This financial cushion can extend operating capacity and reduce the immediate need to raise external capital while the late-stage program advances.
Bears Say
Pre-commercial Business Model
The absence of revenue means the company has not yet demonstrated commercial demand or product economics. Widening losses also show that substantial spending is required before potential approval and launch, leaving results dependent on successful clinical and regulatory execution.
Accelerating Cash Burn
Rapidly increasing operating cash outflows indicate that the business is not self-funding while development activity expands. Continued negative free cash flow can consume liquidity over time and may require additional financing, creating dilution or funding pressure before commercialization.
Deeply Negative Equity
The swing to deeply negative equity represents a major deterioration in net worth and weakens financial flexibility. Although reported debt was minimal, the negative capital position increases dependence on external funding and leaves less balance-sheet capacity to absorb setbacks or delays.
Veradermics, Incorporated News
Veradermics announces results from Part B Phase 2/3 trial of VDPHL01
Veradermics (MANE) announced positive topline results from Part B of its randomized, double-blind, placebo-controlled, registration-directed Phase 2/3 clinical trial evaluating VDPHL01 in over 500 males with mild-to-moderate pattern hair loss.
Veradermics announces trial of VDPHL01 met primary, secondary endpoints
Veradermics (MANE) announced positive topline results from Part A of its randomized, double-blind, placebo-controlled registration-directed Phase 3 clinical trial evaluating VDPHL01, a proprietary, extended-release oral minoxidil formulation, in over 500
MANE FAQ
What was Veradermics, Incorporated’s price range in the past 12 months?
What is Veradermics, Incorporated’s market cap?
When is Veradermics, Incorporated’s upcoming earnings report date?
How were Veradermics, Incorporated’s earnings last quarter?
Is Veradermics, Incorporated overvalued?
Does Veradermics, Incorporated pay dividends?
What is Veradermics, Incorporated’s EPS estimate?
How many shares outstanding does Veradermics, Incorporated have?
What happened to Veradermics, Incorporated’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Veradermics, Incorporated?
What is the TipRanks Smart Score and how is it calculated?
Veradermics, Incorporated Stock Smart Score
Company Description
Veradermics, Incorporated
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Reid Waldman
- Employees
- 51
- Website
- www.veradermics.com
- Address
- 470 James Street, New Haven, CT, 06513, US
Veradermics, Incorporated (MANE) Earnings & Revenues
MANE Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 6 | 8 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 4 | 0 | 6 |






